Replies to post #3697 on Ayala Pharmaceuticals Inc (ADXS)

[James salmon]

Research analysts at HC Wainright boosted their target price on shares of Advaxis (NASDAQ:ADXS) from $25.00 to $30.00 in a report released on Tuesday. The firm currently has a “buy” rating on the biotechnology company’s stock. HC Wainright’s price target suggests a potential upside of 22.35% from the stock’s previous close.

[TheHound]

Good luck with that.